Tiny Health

Tiny Health is a microbiome testing company offering at-home gut and vaginal tests for family members at every life stage, from preconception and pregnancy through infancy, childhood and adulthood. Customers collect stool or vaginal swab samples at home, samples are processed in a CLIA-certified, CAP-accredited lab, and results are returned in roughly two to three weeks with an age-specific report, a list of detected microbes, condition associations, and a personalized action plan covering nutrition, supplements, probiotics and lifestyle changes. Reports are reviewed by in-house microbiology and medical experts, and customers can book functional health coaching sessions with microbiome specialists to discuss results. Retesting is supported so users can track changes over time.

The consumer catalog includes single tests (Adult, Baby ages 0-3, Child ages 3-17, Vaginal Health and Pregnancy gut tests, listed at $249) and annual Tiny+ memberships bundling two tests per year (Adult, Baby, Child, Family, Vaginal and Prenatal, listed at $399/yr). Products are marketed for concerns such as eczema, allergies, asthma, colic, constipation, IBS, antibiotic recovery, C-section gut recovery, inflammation, digestion, UTIs, PCOS and pregnancy complications including preterm birth, gestational diabetes and preeclampsia. Purchases are HSA/FSA eligible via TrueMed.

A business-to-business arm, Powered by Tiny (poweredbytiny.com), sells the same testing to clinicians and clinics through a practitioner portal, with practitioner pricing, bulk and wholesale ordering, shared patient/practitioner results access, sample reports, an education hub and ongoing training. A practitioner-only PRO Gut Health Test adds stool chemistry markers such as secretory IgA, calprotectin, beta-glucuronidase, occult blood and elastase. Practitioner tests are available in all 50 US states except New York, New Jersey and Rhode Island, and in Canada. Tiny Health also runs customer-participation research studies on topics including genetics and the gut microbiome, mold exposure, the oral-gut axis, microbiome age, adult HMOs, childhood allergies and IVF fertility, with partners such as Neurobiologix, Layer Origin, Free to Feed and Bristle Health.

Founding story

Founder Cheryl Sew Hoy had two contrasting births — a first child delivered by C-section who developed mild eczema and a sesame allergy, and a second delivered vaginally with midwife support. Unable to find infant-specific gut tests to track her first child's microbiome recovery, she read scientific literature, consulted a microbiologist, and assembled a team of scientists, physicians and microbiologists, working roughly a year on the problem before Tiny Health was created. She founded the company in 2020.

Business model

Direct-to-consumer sale of at-home microbiome test kits and annual subscription memberships that include two tests per year plus tools and support, complemented by a B2B channel selling tests and a results portal to practitioners and clinics at practitioner and wholesale pricing, including partnerships with companies and clinics.

Product and subscription revenue: single test kits listed at $249 and Tiny+ annual memberships listed at $399 per year, plus practitioner/wholesale kit sales through the Powered by Tiny program; purchases are HSA/FSA eligible through TrueMed.

Traction

The website states more than 100,000 families use Tiny Health; a founder letter dated August 2024 cited over 25,000 families helped in the two years after the 2022 launch, and an October 2025 funding report cited over 80,000 families and individuals. The practitioner arm reports more than 4,000 practitioners. B2B partners named include DYPER, Begin Health, Labcorp, Obvio Health, Astarte Medical and GritWell, with integrations cited with Mayo Clinic's Longevity & Executive Health Clinic, Superpower and Mito Health. The company ranked No. 208 on the 2026 Inc. 5000.

Latest developments

In September 2025 Tiny Health published results of its Infant Restore randomized controlled trial in Pediatric Allergy and Immunology: 54 healthy C-section babies followed for three months, with the group receiving personalized microbiome testing, targeted probiotics and expert guidance showing 83% lower odds of eczema, higher Bifidobacterium infantis abundance (median 61% vs 3.4% in controls at time point 2), increased HMO-degrading sialidase gene levels, a reduced C-section microbiome signature, and fewer reported health conditions. A white paper on the study is promoted to practitioners. The company was also reported in October 2025 to have secured $8.5 million in investment, and ranked No. 208 on the 2026 Inc. 5000.